{
    "clinical_study": {
        "@rank": "70441", 
        "acronym": "BMACD", 
        "arm_group": {
            "arm_group_label": "Transfer of autologous MNC intrathecally", 
            "arm_group_type": "Other", 
            "description": "single arm Intra thecal transplantation of autologous  MNC"
        }, 
        "brief_summary": {
            "textblock": "This study is Single arm, Single Centre trial to check the  Safety and Efficacy of Bone\n      Marrow Derived Autologous mono nuclear cells (100 Million per dose).trial to be conducted\n      for 36 months in patients with diabetes Mellitus in India,Primary outcome measure are\n      abolition or reduction of insulin by>50 percentage by the end of 6 months of ABMSCT-Any\n      reduction  in requirement of Insulin dosage and Improvement in HbA1C Level."
        }, 
        "brief_title": "Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Diabetes Mellitus.", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus.", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "detailed_description": {
            "textblock": "his study is Single arm, Single Centre trial to check the  Safety and Efficacy of Bone\n      Marrow Derived Autologous mono nuclear cells (100 Million per dose).trial to be conducted\n      for 36 months in patients with diabetes Mellitus in India,Primary outcome measure are\n      abolition or reduction of insulin by>50 percentage by the end of 6 months of ABMSCT-Any\n      reduction  in requirement of Insulin dosage and Improvement in HbA1C Level."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient should suffer from Diabetes Mellitus.\n\n          -  Willingness to undergo Bone Marrow derived Autologous cell Therapy.\n\n          -  Ability to comprehend the explained protocol and thereafter give an informed consent\n             as well as sign the required Informed Consent form(ICF) for the study.\n\n          -  Ability and willingness to regular visit to hospital for protocol procedures and\n             follow up\n\n        Exclusion Criteria:\n\n          -  Patient with History of Immunodeficiency HIV+,Hepatitis B ,HBV and History of Life\n             threatening allergic or immune -Mediated Reaction. the site of bone marrow aspiration\n             potentially limiting Procedure. Alcohol and drug abuse / dependence. Patients with\n             History of Hypertension and Hypersensitive."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832441", 
            "org_study_id": "00108"
        }, 
        "intervention": {
            "arm_group_label": "Transfer of autologous MNC intrathecally", 
            "description": "Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval", 
            "intervention_name": "Intra thecal transplantation of autologous MNC", 
            "intervention_type": "Other", 
            "other_name": "Intra thecal transplantation of autologous MNC"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Diabetes Mellitus stem cells [MNCS ]", 
        "lastchanged_date": "April 12, 2013", 
        "location": {
            "contact": {
                "email": "sac2751982@gmail.com", 
                "last_name": "Sachin S Jamadar, D ORTHO", 
                "phone": "+918888788880"
            }, 
            "contact_backup": {
                "email": "drsmitabhoyar@rediffmail.com", 
                "last_name": "Smita S Bhoyar, BAMS PGCR", 
                "phone": "+9372620569"
            }, 
            "facility": {
                "address": {
                    "city": "Pune", 
                    "country": "India", 
                    "state": "Maharashtra", 
                    "zip": "411009"
                }, 
                "name": "Chaitanya Hospital"
            }, 
            "investigator": {
                "last_name": "Anant E Bagul, MS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Diabetes Mellitus.", 
        "overall_contact": {
            "email": "sac2751982@gmail.com", 
            "last_name": "Sachin P Jamadar, D Ortho", 
            "phone": "+918888788880"
        }, 
        "overall_contact_backup": {
            "email": "drsmitabhoyar@rediff.com", 
            "last_name": "Smita S Bhoyar, B.A.M.S.PGCR", 
            "phone": "9372620569"
        }, 
        "overall_official": {
            "affiliation": "CHAITANYA HOSPITAL", 
            "last_name": "ANANT E BAGUL, M.S", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "- Abolition or reduction of insulin by >50 percentage  of ABMSCT by 6 month", 
            "measure": "Abolition or reduction of insulin by >50 percentage", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832441"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chaitanya Hospital, Pune", 
            "investigator_full_name": "Dr. Sachin Jamadar", 
            "investigator_title": "CO-Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Improvement in HbA1C levels as compared to baseline by the end of 6 months .", 
            "measure": "Improvement in HbA1C levels", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Chaitanya Hospital, Pune", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chaitanya Hospital, Pune", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}